Reported Earnings • Aug 01
Full year 2026 earnings released: CA$0.019 loss per share (vs CA$0.052 loss in FY 2025) Full year 2026 results: CA$0.019 loss per share (improved from CA$0.052 loss in FY 2025). Revenue: CA$2.54m (down 20% from FY 2025). Net loss: CA$3.58m (loss narrowed 61% from FY 2025). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. New Risk • Jul 18
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.3m (US$9.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.2m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-CA$15m). Market cap is less than US$10m (CA$13.3m market cap, or US$9.53m). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (CA$1.8m revenue, or US$1.3m). New Risk • Jun 28
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.2m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Negative equity (-CA$15m). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (CA$1.8m revenue, or US$1.2m). Market cap is less than US$100m (CA$15.6m market cap, or US$11.0m). New Risk • Feb 10
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.2m (US$9.70m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.9m free cash flow). Shares are highly illiquid. Negative equity (-CA$15m). Market cap is less than US$10m (CA$13.2m market cap, or US$9.70m). Minor Risk Revenue is less than US$5m (CA$2.3m revenue, or US$1.7m). Announcement • Feb 02
PharmaCielo Ltd., Annual General Meeting, Apr 02, 2026 PharmaCielo Ltd., Annual General Meeting, Apr 02, 2026. Location: ontario, toronto Canada Board Change • Jan 07
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. CFO, Corporate Secretary & Director Ian Atacan was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Aug 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. CFO, Corporate Secretary & Director Ian Atacan was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. New Risk • Apr 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-CA$7.5m). Market cap is less than US$10m (CA$11.4m market cap, or US$7.98m). Minor Risk Revenue is less than US$5m (CA$3.5m revenue, or US$2.4m). Reported Earnings • Mar 02
Full year 2024 earnings released: CA$0.053 loss per share (vs CA$0.10 loss in FY 2023) Full year 2024 results: CA$0.053 loss per share (improved from CA$0.10 loss in FY 2023). Revenue: CA$3.48m (up 126% from FY 2023). Net loss: CA$9.14m (loss narrowed 44% from FY 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings. New Risk • Feb 09
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.6m (US$9.51m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.1m free cash flow). Negative equity (-CA$7.6m). Market cap is less than US$10m (CA$13.6m market cap, or US$9.51m). Minor Risks Share price has been volatile over the past 3 months (18% average weekly change). Revenue is less than US$5m (CA$2.6m revenue, or US$1.8m). Reported Earnings • Dec 01
Third quarter 2024 earnings released: CA$0.016 loss per share (vs CA$0.017 loss in 3Q 2023) Third quarter 2024 results: CA$0.016 loss per share (improved from CA$0.017 loss in 3Q 2023). Revenue: CA$1.33m (up 278% from 3Q 2023). Net loss: CA$2.64m (loss narrowed 4.2% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. New Risk • Nov 07
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.6m (US$9.79m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.4m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-CA$5.4m). Market cap is less than US$10m (CA$13.6m market cap, or US$9.79m). Minor Risks Shareholders have been diluted in the past year (2.9% increase in shares outstanding). Revenue is less than US$5m (CA$1.6m revenue, or US$1.2m). Reported Earnings • Aug 18
Second quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.023 loss in 2Q 2023) Second quarter 2024 results: CA$0.015 loss per share (improved from CA$0.023 loss in 2Q 2023). Revenue: CA$783.7k (up 391% from 2Q 2023). Net loss: CA$2.58m (loss narrowed 28% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Announcement • Apr 11
PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding PharmaCielo Ltd. announced a non-brokered private placement of 9,090,909 units at an issue price of CAD 0.22 per unit for the gross proceeds of CAD 1,999,999.98 on April 10, 2024. Each Unit will be comprised of one common share and one Common Share purchase warrant Each Warrant entitles the holder thereof to purchase one Common Share at a price of CAD 0.30 for a period of 24 months. Closing of the Offering may take place in one or more tranches, provided that the final tranche closing will occur no later than May 25, 2024, being 45 days following the date hereof. Closing of the Offering is subject to regulatory approval including that of the TSX Venture Exchange. The Company has the option to increase the size of the Offering to 4,545,455 Units or CAD 3,000,000. Certain insiders of company and existing investors of Siam Ventures plan to participate in the Offering. Announcement • Dec 28
PharmaCielo Ltd., Annual General Meeting, Feb 20, 2024 PharmaCielo Ltd., Annual General Meeting, Feb 20, 2024. Reported Earnings • Dec 01
Third quarter 2023 earnings released: CA$0.017 loss per share (vs CA$0.034 loss in 3Q 2022) Third quarter 2023 results: CA$0.017 loss per share (improved from CA$0.034 loss in 3Q 2022). Revenue: CA$351.7k (down 26% from 3Q 2022). Net loss: CA$2.76m (loss narrowed 47% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Announcement • Oct 07
PharmaCielo Ltd. announced that it has received CAD 4.78 million in funding On October 6, 2023, PharmaCielo Ltd., closed the transaction. The company issued 1,500 units at a price of CAD 1,000 per unit for the gross proceeds of CAD 1,500,000 in its second and final tranche closing. New Risk • Aug 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$6.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CA$6.5m free cash flow). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (5.9% increase in shares outstanding). Revenue is less than US$5m (CA$2.9m revenue, or US$2.2m). Market cap is less than US$100m (CA$27.6m market cap, or US$20.4m). Reported Earnings • Aug 31
Second quarter 2023 earnings released: CA$0.023 loss per share (vs CA$0.023 loss in 2Q 2022) Second quarter 2023 results: CA$0.023 loss per share (in line with 2Q 2022). Revenue: CA$159.5k (down 93% from 2Q 2022). Net loss: CA$3.58m (loss widened 1.9% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Recent Insider Transactions Derivative • Jun 15
CEO, President & Chairman of the Board exercised options to buy CA$33k worth of stock. On the 12th of June, William Petron exercised options to buy 167k shares at a strike price of around CA$0.48, costing a total of CA$80k. This transaction amounted to 13% of their direct individual holding at the time of the trade. Since June 2022, William's direct individual holding has increased from 796.35k shares to 1.27m. Company insiders have collectively bought CA$478k more than they sold, via options and on-market transactions, in the last 12 months. New Risk • Jun 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CA$7.5m free cash flow). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Revenue is less than US$5m (CA$4.9m revenue, or US$3.7m). Market cap is less than US$100m (CA$37.5m market cap, or US$28.0m). Reported Earnings • Jun 03
First quarter 2023 earnings released: CA$0.023 loss per share (vs CA$0.019 loss in 1Q 2022) First quarter 2023 results: CA$0.023 loss per share (further deteriorated from CA$0.019 loss in 1Q 2022). Revenue: CA$786.5k (down 35% from 1Q 2022). Net loss: CA$3.56m (loss widened 22% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Reported Earnings • May 03
Full year 2022 earnings released: CA$0.096 loss per share (vs CA$0.18 loss in FY 2021) Full year 2022 results: CA$0.096 loss per share (improved from CA$0.18 loss in FY 2021). Revenue: CA$5.31m (up 173% from FY 2021). Net loss: CA$14.5m (loss narrowed 46% from FY 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Dec 02
Independent Lead Director recently bought CA$83k worth of stock On the 25th of November, Marc Lustig bought around 200k shares on-market at roughly CA$0.42 per share. This transaction amounted to 5.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$690k more in shares than they have sold in the last 12 months. Board Change • Nov 16
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Member of Medical & Scientific Advisory Board Anders Milton is the most experienced director on the board, commencing their role in 2016. Independent Lead Director Marc Lustig was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Reported Earnings • Oct 29
Third quarter 2022 earnings released: CA$0.034 loss per share (vs CA$0.059 loss in 3Q 2021) Third quarter 2022 results: CA$0.034 loss per share (improved from CA$0.059 loss in 3Q 2021). Revenue: CA$475.3k (down 2.0% from 3Q 2021). Net loss: CA$5.18m (loss narrowed 41% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 30
Second quarter 2022 earnings released: CA$0.023 loss per share (vs CA$0.049 loss in 2Q 2021) Second quarter 2022 results: CA$0.023 loss per share (up from CA$0.049 loss in 2Q 2021). Revenue: CA$2.12m (up 375% from 2Q 2021). Net loss: CA$3.52m (loss narrowed 51% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Board Change • Aug 01
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Member of Medical & Scientific Advisory Board Anders Milton is the most experienced director on the board, commencing their role in 2016. Independent Lead Director Marc Lustig was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Announcement • Jul 29
PharmaCielo Ltd. Announces Board and Executive Changes PharmaCielo also announced that its board of directors has appointed Ian Atacan to the board, effective July 25, 2022. Mr. Atacan has been the Company's Chief Financial Officer since June 7, 2021. PharmaCielo has appointed Dr. Decio Rabelo de Castro Filho as Chief Medical Officer of the Company, to advance the Company's visibility within physician communities and with pharmaceutical organizations in Latin America, Europe and other key markets globally. Dr. de Castro Filho is a medical doctor with over 20 years of experience in occupational medicine and marketing. During the course of his career, Dr. de Castro Filho has also acted as an expert medical witness for several large Brazilian companies. Dr. de Castro Filho is a graduate of the medical program at Pontifical Catholic University of Campinas and has a master's degree in Marketing from Escola Superior de Propaganda e Marketing ESPM in São Paulo. He holds a degree in cannabinoid medicine from the Wecann Academia school. Recent Insider Transactions • Jul 17
CEO, President & Chairman of the Board recently bought CA$67k worth of stock On the 8th of July, Bill Petron bought around 150k shares on-market at roughly CA$0.44 per share. This was the largest purchase by an insider in the last 3 months. Bill has been a buyer over the last 12 months, purchasing a net total of CA$95k worth in shares. Announcement • Jul 01
PharmaCielo Ltd., Annual General Meeting, Sep 01, 2022 PharmaCielo Ltd., Annual General Meeting, Sep 01, 2022. Recent Insider Transactions Derivative • Jun 25
CEO, President & Chairman of the Board exercised options to buy CA$87k worth of stock. On the 20th of June, Bill Petron exercised options to buy 167k shares at a strike price of around CA$0.48, costing a total of CA$80k. This transaction amounted to 21% of their direct individual holding at the time of the trade. Since December 2021, Bill's direct individual holding has increased from 20.00k shares to 796.35k. Company insiders have collectively bought CA$3.6m more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Jun 01
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: CA$0.019 loss per share (up from CA$0.047 loss in 1Q 2021). Net loss: CA$2.91m (loss narrowed 56% from 1Q 2021). Revenue missed analyst estimates by 7.4%. Earnings per share (EPS) also missed analyst estimates by 200%. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. Board Change • May 31
High number of new directors Director Will Nicholas was the last director to join the board, commencing their role in 2021. Reported Earnings • May 01
Full year 2021 earnings: Revenues miss analyst expectations Full year 2021 results: Net loss: CA$26.6m (loss narrowed 39% from FY 2020). Revenue missed analyst estimates by 7.4%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Board Change • Apr 27
High number of new directors Director Will Nicholas was the last director to join the board, commencing their role in 2021. Recent Insider Transactions • Mar 30
Independent Lead Director recently bought CA$92k worth of stock On the 25th of March, Marc Lustig bought around 125k shares on-market at roughly CA$0.74 per share. In the last 3 months, they made an even bigger purchase worth CA$292k. Insiders have collectively bought CA$2.4m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Mar 16
Independent Lead Director recently bought CA$292k worth of stock On the 14th of March, Marc Lustig bought around 400k shares on-market at roughly CA$0.73 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$2.3m more in shares than they have sold in the last 12 months. Announcement • Dec 23
PharmaCielo Ltd. announced that it expects to receive CAD 15 million in funding PharmaCielo Ltd announced a non-brokered private placement of 15,000 debenture units at an issue price of CAD 1,000 per unit for gross proceeds of CAD 15,000,000 on December 22, 2021. The transaction may include participation from insiders, including directors and management. The Company expects to issue the Units on or about December 30, 2021, in one or more closings, subject to the approval of the TSX Venture Exchange. Each will Unit consist of $1,000 principal amount of 11% secured debentures and 250 non-transferable common share purchase warrants. Each Debenture Warrant will entitle the holder for a period of 36 months from the initial closing date to acquire one common share of the Company at an exercise price equal to a 50% premium over the market price of the Common Shares at the time of the initial closing. The Debentures will bear interest at a rate of 11.0% per annum, will mature 36 months from the date of initial closing date, and will be guaranteed by Holdings. The Company will have the right to redeem any or all of the Debentures from time to time at the following percentages of face value: (i) 105% at any time prior to the first anniversary of the initial closing date; (ii) 103% at any time on or after the first anniversary of the initial closing date and prior to the second anniversary of the initial closing date; and (iii) 101% thereafter, in each case together with accrued and unpaid interest to, but not including, the date of redemption. The Debentures, Debenture Warrants and any Common Shares issuable upon exercise of the Debenture Warrants will be subject to a four-month hold period under applicable Canadian securities laws, starting from the date of issuance of the corresponding Units. Reported Earnings • Nov 28
Third quarter 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2021 results: CA$0.059 loss per share (up from CA$0.083 loss in 3Q 2020). Net loss: CA$8.75m (loss narrowed 11% from 3Q 2020). Revenue missed analyst estimates by 7.4%. Earnings per share (EPS) exceeded analyst estimates by 200%. Earnings per share (EPS) surpassed analyst estimates by 200%. Over the next year, revenue is forecast to grow 683%, compared to a 135% growth forecast for the industry in Canada. Recent Insider Transactions • Sep 09
Independent Lead Director recently bought CA$1.8m worth of stock On the 3rd of September, Marc Lustig bought around 2m shares on-market at roughly CA$1.10 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$1.8m more in shares than they have sold in the last 12 months. Director Overboarding • Sep 02
Director Marc Lustig has joined 5th company board Independent Lead Director Marc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 02
Director Marc Lustig has joined 5th company board Independent Lead Director Marc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 02
Director Marc Lustig has joined 5th company board Independent Lead Director Marc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 02
Director Marc Lustig has joined 5th company board Independent Lead Director Marc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Executive Departure • Aug 24
CEO, President & Director Henning von Koss has left the company On the 20th of August, Henning von Koss' tenure as CEO, President & Director of the company ended after less than a year in the role. We don't have any record of a personal shareholding under Henning's name. A total of 4 executives have left over the last 12 months. The current median tenure of the management team is 1.63 years, which is considered inexperienced in the Simply Wall St Risk Model. Under Henning's leadership, the company delivered a total shareholder return of -5.0%. Announcement • Aug 22
Pharmacielo Ltd. Provides Revenue Guidance for the Second Half of 2021 PharmaCielo Ltd. provided revenue guidance for the second half of 2021. For the period, the company expects revenue growth to accelerate as sales agreements and initial commercial sales translate into higher recurring revenue and the shipment of additional value-added products beyond CBD isolate, with better margin profiles. Reported Earnings • Aug 21
Second quarter 2021 earnings released Second quarter 2021 results: Net loss: CA$7.22m (loss narrowed 6.4% from 2Q 2020). Executive Departure • Jun 12
Independent Chairman of the Board Simon Langelier has left the company On the 10th of June, Simon Langelier's tenure as Independent Chairman of the Board ended. As of March 2021, Simon still personally held 788.46k shares (CA$678k worth at the time). A total of 4 executives have left over the last 12 months. The current median tenure of the management team is 2.42 years. Executive Departure • Jun 04
Chief Financial Officer Scott Laitinen has left the company During their tenure, earnings grew by 51% annually compared to the industry average of 0.9%. On the 1st of June, Scott Laitinen left the company after 5.4 in the role. We don't have any record of a personal shareholding under Scott's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 2.42 years. Reported Earnings • Jun 02
First quarter 2021 earnings released: CA$0.047 loss per share (vs CA$0.064 loss in 1Q 2020) The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: CA$675.3k (up 31% from 1Q 2020). Net loss: CA$6.54m (loss widened 3.5% from 1Q 2020). Recent Insider Transactions • Apr 10
Independent Director recently bought CA$115k worth of stock On the 7th of April, Claudia Jimenez Jaramillo bought around 95k shares on-market at roughly CA$1.21 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$27k more in shares than they have sold in the last 12 months. Reported Earnings • Apr 09
Third quarter 2020 earnings released: CA$0.083 loss per share (vs CA$0.04 loss in 3Q 2019) Third quarter 2020 results: Net loss: CA$9.79m (loss widened 156% from 3Q 2019). Announcement • Feb 19
PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate PharmaCielo Ltd. announced that it has exported its first commercial shipment of THC-free broad-spectrum distillate to an existing customer with operations in the U.K. and the E.U. This higher-grade, higher-value extract delivery succeeds earlier shipments of 1,000Kg of CBD isolate PharmaCielo exported to this Customer in fourth quarter-2020. This shipment of the broad-spectrum distillate marks PharmaCielo's inaugural delivery of a new product out of its extended product portfolio and complements earlier exports of the Company's CBD isolate to the U.K., the U.S., Switzerland and other E.U. markets. Is New 90 Day High Low • Feb 11
New 90-day high: CA$2.68 The company is up 362% from its price of CA$0.58 on 12 November 2020. The Canadian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 109% over the same period. Announcement • Feb 03
PharmaCielo Provides Update on GMP Compliance Process PharmaCielo Ltd. provided an update on its ongoing Good Manufacturing Practices (GMP) compliance process. As planned, the Company is preparing itself for the GMP audit process in partnership with NODO Interactivo ("NODO"), a consultancy specializing in the implementation and maintenance of GMP and Good Laboratory Practice (GLP) quality management systems for the pharmaceutical, cosmetic, food and related industries. PharmaCielo expects to receive Colombian GMP certification during the first quarter of this year. The Company's Rionegro facility is Colombia's largest cannabis processing centre, capable of processing 360 tonnes of biomass annually. In addition, PharmaCielo Mexico, the Company's joint venture ("JV") with MINO Labs S.A. de C.V. ("MINO Labs"), has initiated a GMP pre-audit process. This move comes in tandem with a recent announcement by the Mexican government that it has published a much-anticipated legal framework for the medical cannabis space, including a provision for the import of medicinal extracts and products. PharmaCielo Mexico is positioned to be an early mover in this high-potential market and to become a primary supplier of premium-quality medicinal-grade extracts to the Mexican market. The Company expects to receive Mexican GMP certification during the second quarter of 2021. Announcement • Dec 20
PharmaCielo Ltd. Announces the Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity PharmaCielo Ltd. announced that the company has expanded investor relations support capacity with the appointment of Caroline Lenardon to provide investor relations services to the Company with a focus on retail investment. The institutional investor market will continue to be supported by the existing contractor. Recent Insider Transactions • Dec 19
CEO, President & Director recently sold CA$88k worth of stock On the 17th of December, Henning von Koss sold around 50k shares on-market at roughly CA$1.76 per share. This was the largest sale by an insider in the last 3 months. This was Henning's only on-market trade for the last 12 months. Is New 90 Day High Low • Dec 17
New 90-day high: CA$2.18 The company is up 340% from its price of CA$0.49 on 18 September 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 51% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Announcement • Dec 13
PharmaCielo Ltd., PharmaCielo Colombia Holdings S.A.S. Enter into Strategic Alliance with AssuredTrans Inc PharmaCielo Ltd., PharmaCielo Colombia Holdings S.A.S., announced that it has entered into a strategic alliance with AssuredTrans Inc. The alliance between AssuredTrans and PharmaCielo provides U.S. CBD buyers a value proposition that guarantees independent product quality assurance, reduced supply chain costs and customized product specifications for multiple manufacturing needs. AssuredTrans's patent pending ecosystem ensures and insures both product and material specifications, protecting both the manufacturer and the supplier, a very unique solution in the current market. This proprietary system mitigates the financial and material risk associated with purchasing raw ingredients such as CBD extracts, giving large manufacturers the peace of mind and ability to produce at scale. AssuredTrans is partnered with a leading international specialist insurance provider, an 800-laboratory testing service and customer-directed audit provision via an established logistic audit and certification firm with global offices in over 70 countries, including Colombia. Analyst Estimate Surprise Post Earnings • Dec 02
Revenue and earnings miss expectations Revenue missed analyst estimates by 98%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 2,298%, compared to a 129% growth forecast for the Pharmaceuticals industry in Canada. Announcement • Nov 19
PharmaCielo Ltd. Delivers Its First Commercial Shipment of Medicinal Grade CBD Isolate PharmaCielo Ltd. announced that it has delivered its first commercial shipment of medicinal grade CBD isolate (the "Initial Shipment") to a well-established, bulk distributor and white label manufacturer based in the U.K., with sales and distribution operations in the U.K., and the E.U. (the "Customer"). In addition, the Company has reached an interim sales agreement with the Customer, lasting until the end of Q1-2021, at which point PharmaCielo expects to have submitted a Novel Foods authorization application for its range of CBD extracts. The interim, renewable agreement enables continued shipments for the remainder of 2020 and calls for the shipment of up to 1,000 kg of CBD Isolate and Broad-Spectrum CBD based on the Customer's specifications, during Q1-2021. With submission of the Novel Foods authorization application prior to March 31, the Company expects to be in a position to subsequently expand both volume and exported consumable product types during fiscal 2021 in accordance with regulatory requirements. In addition, the Company has reached an interim sales agreement with the Customer, lasting until the end of Q1-2021, at which point PharmaCielo expects to have submitted a Novel Foods authorization application for its range of CBD extracts. The interim, renewable agreement enables continued shipments for the remainder of 2020 and calls for the shipment of up to 1,000 kg of CBD Isolate and Broad-Spectrum CBD based on the Customer's specifications, during Q1-2021. With submission of the Novel Foods authorization application prior to March 31, the Company expects to be in a position to subsequently expand both volume and exported consumable product types during fiscal 2021 in accordance with regulatory requirements. Is New 90 Day High Low • Nov 19
New 90-day high: CA$0.74 The company is up 16% from its price of CA$0.64 on 21 August 2020. The Canadian market is up 4.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Announcement • Nov 07
PharmaCielo Ltd. Announces the First Harvest Cycle of Six High-THC Cultivars PharmaCielo Ltd. announced the first harvest cycle of six high-THC cultivars. The harvest from 5.5 hectares of open-air greenhouse at the company's Rionegro complex is expected to yield more than 10 tonnes of dry flower, which will be processed at PharmaCielo's operational processing and extraction centre (PEC) and destined for export. Harvest of the cultivars by hand will continue to year-end, with processing commencing in coming weeks. Each of the six cultivars is unique and proprietary, developed through the horticultural expertise of the PharmaCielo team, and registered with the Colombian government. Blending of the extracts of the cultivars delivers an unparalleled psychoactive product profile appropriate for medicinal application with the necessary and consistent high quality required. As PharmaCielo moves to produce high-THC extracts in-house in its Rionegro complex, the Company continues in parallel to expand its CBD-based cultivation footprint through external growers, with the first contract already enacted in mid-August. This dual-pronged approach is being pursued to enable PharmaCielo to achieve a flexible industrial-scale production that is both cost-effective and flexible and can be scaled up as needed. Announcement • Nov 04
PharmaCielo Ltd. announced that it expects to receive CAD 5 million in funding PharmaCielo Ltd. (TSXV:PCLO) announced a private placement of 10,000,000 units at a price of CAD 0.50 per unit for gross proceeds of CAD 5,000,000 led by individual investor Marc Lustig on November 2, 2020. Each unit will be comprised of one common share and one half of one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of CAD 0.65 for a period of 24 months. The company has the option to increase the size of the transaction to CAD 10,000,000. The transaction is subject to regulatory approvals including that of the TSX Venture Exchange. The company may pay a commission or finder's fee to eligible persons from the gross proceeds raised under the transaction. As part of the transaction, Marc Lustig will join the company's board of directors as a lead director. The transaction is expected to close on November 20, 2020. Announcement • Nov 03
PharmaCielo Ltd. Appoints Marc Lustig as Lead Director PharmaCielo Ltd. announced that Marc Lustig has agreed to join the Company's board of directors (the "Board") as Lead Director, subject to gross proceeds of $5.0 million being raised under the Offering. Mr. Lustig remains the Chairman of IM Cannabis Corp. and Trichome Financial Corp. and a director of Cresco Labs Inc. Announcement • Sep 22
PharmaCielo Ltd. Expands Portfolio of Cannabis Extracts to Meet Global B2b Medical-Grade Market Demand PharmaCielo Ltd. announced that it has begun sales and distribution of an expanded range of medicinal-grade cannabis extracts cultivated and produced at its Rionegro facilities. PharmaCielo has been enabled to address customer product inquiries based on technical experience to date combined with increased laboratory and processing capabilities and allowing it to begin commercial production of a significantly expanded range of extract products that began with CBD Isolate and now includes Broad Spectrum Oil, CBD Broad Spectrum Distillate, Water Soluble CBD, CBD Tincture, CBD Distillate Tincture, Full Spectrum Oil Tincture, THC:CBD Formulations and THC Distillate. Is New 90 Day High Low • Sep 18
New 90-day low: CA$0.54 The company is down 25% from its price of CA$0.72 on 19 June 2020. The Canadian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 
